Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

On-Demand CME Videos

Tips in the Use of IL-17 Inhibitors in Dermatology

About

This activity was recorded at the Fall Clinical Dermatology Conference 2023. 

Tips in the Use of IL-17 Inhibitors in Dermatology

This activity is supported by an educational grant from UCB, Inc.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

December 4, 2023

Expiration Date:

December 31, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Differentiate between the IL-17 inhibitors and IL-23 inhibitors for the management of chronic inflammatory dermatologic disorders such as psoriasis, psoriatic arthritis, and hidradenitis suppurativa

  • Overview the role of IL-17 inhibitors for the management of psoriasis, psoriatic arthritis, and hidradenitis suppurativa

  • Describe how to manage patients with IL-17 inhibitors over the continuum of care with particular attention to the ease of dealing with side effects

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Joseph
Joseph Merola, MD, MMSc

Professor and Chair
University of Texas Southwestern Medical Center
Dallas, TX 

Bruce
Bruce Strober, MD, PhD

Clinical Professor of Dermatology
Yale University School of Medicine
New Haven, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Joseph F. Merola, MD, MMSc

Grant/Research Support: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron Consultant: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron

Bruce E. Strober, MD, PhD

Consultant: AbbVie, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics

Speakers’ Bureau or Honoraria: AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme                                

Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry

Investigator: Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis

Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis
Ownership Interest: Connect Biopharma

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved